Alpha Or Leukocyte Patents (Class 424/85.7)
  • Publication number: 20110311476
    Abstract: The present invention provides novel immunotherapeutic compositions and methods useful for treating or preventing microbial infections, weakened immune systems, diseases in which cells have become obligately anaerobic and cellular proliferative disorders including cancer. The immunotherapeutics herein use benzaldehyde derivatives, precursors and intermediaries alone or in combination with additional therapeutic agents to stimulate the immune system and inhibit cellular proliferation.
    Type: Application
    Filed: August 19, 2011
    Publication date: December 22, 2011
    Inventor: Joe Ernest BROWN
  • Publication number: 20110311481
    Abstract: Methods and compositions for contributing to the treatment of cancers, especially ovarian tumors, are disclosed. The methods and compositions utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of chemotherapeutic agent(s) (e.g., cisplatin and/or cyclophosphamide).
    Type: Application
    Filed: August 29, 2011
    Publication date: December 22, 2011
    Applicants: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, SPECTRUM PHARMACEUTICALS, INC.
    Inventors: Anil Gulati, Guru Reddy, Luigi Lenaz
  • Publication number: 20110313230
    Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Application
    Filed: April 1, 2011
    Publication date: December 22, 2011
    Inventors: Terrance Grant Johns, Andrew Mark Scott, Gerd Ritter, Achim Jungbluth, Elizabeth Stockert, Stephen Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice, Anne Murray, George Mark, Lloyd J. Old, Edward B. Reilly, Andrew C. Phillips, Jonathan A. Meulbroek, Fritz G. Buchanan
  • Publication number: 20110311477
    Abstract: The present invention provides novel immunotherapeutic compositions and methods useful for treating or preventing microbial infections, weakened immune systems, diseases in which cells have become obligately anaerobic and cellular proliferative disorders including cancer. The immunotherapeutics herein use benzaldehyde derivatives, precursors and intermediaries alone or in combination with additional therapeutic agents to stimulate the immune system and inhibit cellular proliferation.
    Type: Application
    Filed: August 19, 2011
    Publication date: December 22, 2011
    Inventor: Joe Ernest Brown
  • Publication number: 20110311478
    Abstract: The present invention provides novel immunotherapeutic compositions and methods useful for treating or preventing microbial infections, weakened immune systems, diseases in which cells have become obligately anerobic and cellular proliferative disorders including cancer. The immunotherapeutics herein use benzaldehyde derivatives, precursors and intermediaries alone or in combination with additional therapeutic agents to stimulate the immune system and inhibit cellular proliferation.
    Type: Application
    Filed: August 19, 2011
    Publication date: December 22, 2011
    Inventor: Joe Ernest BROWN
  • Publication number: 20110305631
    Abstract: Disclosed herein are compositions and methods of use comprising combinations of anti-CD22 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-CD22 antibody or may be separately administered, either before, simultaneously with or after the anti-CD22 antibody. In preferred embodiments, the therapeutic agent is an antibody or fragment thereof that binds to an antigen different from CD22, such as CD19, CD20, CD21, CD22, CD23, CD37, CD40, CD40L, CD52, CD80 and HLA-DR. However, the therapeutic agent may an immunomodulator, a cytokine, a toxin or other therapeutic agent known in the art. More preferably, the anti-CD22 antibody is part of a DNL complex, such as a hexavalent DNL complex. Most preferably, combination therapy with the anti-CD22 antibody or fragment and the therapeutic agent is more effective than the antibody alone, the therapeutic agent alone, or the combination of anti-CD22 antibody and therapeutic agent that are not conjugated to each other.
    Type: Application
    Filed: August 19, 2011
    Publication date: December 15, 2011
    Applicant: IMMUNOMEDICS, INC.
    Inventors: Serengulam V. Govindan, David M. Goldenberg
  • Patent number: 8075916
    Abstract: A biodegradable and thermosensitive poly(organophosphazene) with a functional group, a preparation method thereof, and a use thereof for delivery of bioactive substances are provided.
    Type: Grant
    Filed: May 17, 2008
    Date of Patent: December 13, 2011
    Assignee: Korea Institute of Science and Technology
    Inventors: Soo-Chang Song, Mi-Ran Park, Sun-Mi Lee
  • Patent number: 8075878
    Abstract: An antiviral/immunomodulatory response in an animal is induced by oral administration to an infected animal, including humans, of a human ?-interferon. Methods of conferring resistance or mitigating the effects of exposure to a virus including avian influenza are described.
    Type: Grant
    Filed: June 18, 2007
    Date of Patent: December 13, 2011
    Assignee: Hemispherx Biopharma
    Inventors: William A. Carter, David Strayer
  • Patent number: 8075877
    Abstract: An antiviral/immunomodulatory response in an animal is induced by oral administration to an infected animal, including humans, of a human ?-interferon. Methods of conferring resistance or mitigating the effects of exposure to a virus including avian influenza are described.
    Type: Grant
    Filed: March 2, 2007
    Date of Patent: December 13, 2011
    Assignee: Hemispherx Biopharma
    Inventors: William A. Carter, David R Strayer
  • Publication number: 20110300066
    Abstract: Disclosed herein are compositions and methods of use comprising combinations of anti-CD74 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-CD74 antibody or may be separately administered, either before, simultaneously with or after the anti-CD74 antibody. In preferred embodiments, the therapeutic agent is an antibody or fragment thereof that binds to an antigen different from CD74, such as CD19, CD20, CD21, CD22, CD23, CD37, CD40, CD40L, CD52, CD80, IL-6, CXCR4 and HLA-DR. However, the therapeutic agent may an immunomodulator, a cytokine, a toxin or other therapeutic agent known in the art. More preferably, the anti-CD74 antibody is part of a DNL complex, such as a hexavalent DNL complex. Most preferably, combination therapy with the anti-CD74 antibody or fragment and the therapeutic agent is more effective than the antibody alone, the therapeutic agent alone, or the combination of anti-CD74 antibody and therapeutic agent that are not conjugated to each other.
    Type: Application
    Filed: August 15, 2011
    Publication date: December 8, 2011
    Applicant: IMMUNOMEDICS, INC.
    Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
  • Publication number: 20110300105
    Abstract: The present invention concerns methods and compositions for forming PEGylated complexes of defined stoichiometry and structure. In preferred embodiments, the PEGylated complex is formed using dock-and-lock technology, by attaching a therapeutic agent to a DDD sequence and attaching a PEG moiety to an AD sequence and allowing the DDD sequence to bind to the AD sequence in a 2:1 stoichiometry, to form PEGylated complexes with two therapeutic agents and one PEG moiety. In alternative embodiments, the therapeutic agent may be attached to the AD sequence and the PEG to the DDD sequence to form PEGylated complexes with two PEG moieties and one therapeutic agent. In more preferred embodiments, the therapeutic agent may comprise any peptide or protein of physiologic or therapeutic activity, preferably a cytokine, more preferably interferon-?2b. The PEGylated complexes exhibit a significantly slower rate of clearance when injected into a subject and are of use for treatment of a wide variety of diseases.
    Type: Application
    Filed: July 7, 2011
    Publication date: December 8, 2011
    Applicant: IBC PHARMACEUTICALS, INC.
    Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
  • Publication number: 20110300104
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the Hepatitis C Virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the Hepatitis C Virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: June 3, 2011
    Publication date: December 8, 2011
    Inventors: Yao-Ling Qiu, Ce Wang, Hui Cao, Xiaowen Peng, Datong Tang, Yat Sun Or
  • Publication number: 20110293565
    Abstract: The invention relates to synthetic chemical compositions that are useful for modulation of Toll-Like Receptor (TLR)-mediated immune responses. In particular, the invention relates to agonists of Toll-Like Receptor 9 (TLR9) that generate unique cytokine and chemokine profiles.
    Type: Application
    Filed: January 28, 2010
    Publication date: December 1, 2011
    Applicant: IDERA PHARMACEUTICALS, INC.
    Inventors: Ekambar Kandimalla, Mallikarjuna Putta, Daqing Wang, Dong Yu, Lakshmi Bhagat, Sudhir Agrawal
  • Publication number: 20110293511
    Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Application
    Filed: April 1, 2011
    Publication date: December 1, 2011
    Inventors: Terrance Grant Johns, Andrew Mark Scott, Gerd Ritter, Achim Jungbluth, Elizabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice, Anne Murray, George Mark, Lloyd J. Old, Edward B. Reilly, Andrew C. Phillips, Jonathan A. Meulbroek, Fritz G. Buchanan, Stephen Stockert
  • Publication number: 20110293516
    Abstract: The present invention concerns compositions comprising and methods of identification and use of targeting peptides for placenta or adipose tissue. In certain embodiments, the targeting peptides comprise part or all of SEQ ID NO:5-11, SEQ ID NO:13-22 or SEQ ID NO:144. The peptides may be attached to various therapeutic agents for targeted delivery. Adipose-targeting peptides may be used in methods for weight control, inducing weight loss and treating lipodystrophy syndrome. Adipose-targeting may also be accomplished using other binding moieties selectively targeted to adipose receptors, such as a prohibitin receptor protein complex. Placenta-targeting peptides may be used to interfere with pregnancy, induce labor and/or for targeted delivery of therapeutic agents to placenta and/or fetus. In other embodiments, receptors identified by binding to placenta-targeting peptides may be used to screen compounds for potential teratogenicity.
    Type: Application
    Filed: April 11, 2011
    Publication date: December 1, 2011
    Inventors: RENATA PASQUALINI, WADIH ARAP, MIKHAIL G. KOLONIN
  • Publication number: 20110286961
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Application
    Filed: December 1, 2010
    Publication date: November 24, 2011
    Inventors: Makonen Belema, Jeffrey Lee Romine, Van N. Nguyen, Gan Wang, Omar D. Lopez, Denis R. St. Laurent, Qi Chen, John A. Bender, Zhong Yang, Piyasena Hewawasam, Ningning Xu, Nicholas A. Meanwell, John A. Easter, Bao-Ning Su, Michael J. Smith
  • Publication number: 20110286967
    Abstract: A polypeptide and polynucleotides encoding same comprising carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to an IFN protein are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.
    Type: Application
    Filed: July 28, 2011
    Publication date: November 24, 2011
    Inventors: Fuad Fares, Udi Eyal Fima
  • Publication number: 20110286969
    Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as wet! as methods of using them to treat disorders associated with the HCV protease An illustrative inventsve compound is shown below: Formula (I).
    Type: Application
    Filed: December 10, 2009
    Publication date: November 24, 2011
    Applicant: SCHERING CORPORATION
    Inventors: Malcolm MacCoss, F. George Njoroge, Frank Bennett, Srikanth Venkatraman, Joseph A. Kozlowski, Wensheng Yu, Paul E. McNamara, Pernilla R. Royster
  • Publication number: 20110286968
    Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.
    Type: Application
    Filed: June 21, 2011
    Publication date: November 24, 2011
    Inventors: Ross Kedl, Phillip J. Sanchez, Catherine Haluszczak
  • Publication number: 20110286962
    Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
    Type: Application
    Filed: May 26, 2011
    Publication date: November 24, 2011
    Inventors: Jean-Pierre SOMMADOSSI, Gilles Gosselin, Claire Pierra, Christian Perigaud, Suzanne Peyrottes
  • Publication number: 20110280833
    Abstract: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, and/or lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.
    Type: Application
    Filed: June 24, 2011
    Publication date: November 17, 2011
    Applicant: CUREDM GROUP HOLDINGS, LLC
    Inventors: Claresa S. Levetan, Loraine V. Upham
  • Publication number: 20110280829
    Abstract: Low molecular weight sulphated L-fucose polysaccharide fraction having a molecular weight ranging from 11 to 30 kDa when measured with TEST A, a sulphate content ranging from 10 and 50% w/w relative to the total weight of the fraction, a fucosis content ranging from 30 and 70% w/w relative to the total weight of the fraction, and a polydispersity index ranging from 1 and 2, wherein the fraction is obtainable by free radical depolymerisation of a crude fucan of vegetal origin; process for manufacturing same; pharmaceutical composition and medicament containing same and their use for inhibiting neovascularisation.
    Type: Application
    Filed: January 7, 2010
    Publication date: November 17, 2011
    Applicant: THERAPOL
    Inventors: Laurent David, Laetitia Frank, Rosa Siali, Jean Huet
  • Publication number: 20110274654
    Abstract: Provided herein are triazole FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, X, RB, and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
    Type: Application
    Filed: May 5, 2011
    Publication date: November 10, 2011
    Inventors: Adilah BAHADOOR, Alfredo C. Castro, Lawrence K. Chan, Gregg F. Keaney, Marta Nevalainen, Vesa Nevalainen, Stephane Peluso, Thomas T. Tibbitts
  • Publication number: 20110274648
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Application
    Filed: November 4, 2010
    Publication date: November 10, 2011
    Inventors: Rico Lavoie, John A. Bender, Zhong Yang, Makonen Belema, Omar D. Lopez, Qi Chen, Gan Wang, Piyasena Hewawasam
  • Publication number: 20110274658
    Abstract: Aspects of the invention provide methods for harnessing the potential of proteins that occur naturally (e.g., in humans) and that have serious but finite toxicity. Aspects of the invention relate to a quantitative systems-biological and structural approach to design a class Mof chimeric proteins that avoid the toxicity of protein drugs while retaining their desired activities. In particular, chimeric proteins containing a variant form of a natural protein fused to a targeting moiety may be administered to a subject to target a signal (e.g.
    Type: Application
    Filed: April 5, 2008
    Publication date: November 10, 2011
    Applicant: President and Fellows of Harvard College
    Inventors: Pamela A. Silver, Pablo Cironi, David G. Miguez
  • Publication number: 20110274656
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating Hepatitis C, comprising the roots extract of Platycodon grandiflorum and/or saponin components in Platycodon grandiflorum useful as an antiviral agent. The composition of the present invention has no harm to human and inhibits the proliferation of Hepatitis C virus, so that it can be effectively used as a preventive or therapeutic agent for Hepatitis C.
    Type: Application
    Filed: January 21, 2010
    Publication date: November 10, 2011
    Applicant: B&C Biopharm Co., Ltd.
    Inventors: Jong Woo Kim, Sang Wook Lee, Sang Jin Park, Jung Cheul Shin, Jae Won Yang, Jong Hwan Lim
  • Publication number: 20110274655
    Abstract: Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
    Type: Application
    Filed: May 5, 2011
    Publication date: November 10, 2011
    Applicant: Infinity Pharmaceuticals
    Inventors: Adilah BAHADOOR, Alfredo C. Castro, Lawrence K. Chan, Gregg F. Keaney, Marta Nevalainen, Vesa Nevalainen, Stephane Peluso, Daniel A. Snyder, Thomas T. Tibbitts
  • Publication number: 20110270212
    Abstract: Methods and devices for treating patients having chronic hepatitis C infection so as to eradicate detectable HCV-RNA and/or inhibit the emergence of a drug resistant HCV variant are disclosed. Certain methods of the invention involve the use of a continuous infusion pump in a multiphasic combination therapy using a therapeutically effective amount of a small molecule inhibitor such as ribavirin and a therapeutically effective amount of interferon-?.
    Type: Application
    Filed: October 3, 2008
    Publication date: November 3, 2011
    Applicant: MEDTRONIC, INC.
    Inventors: William P. Van Antwerp, Thomas J. Vasicek
  • Publication number: 20110268700
    Abstract: The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin and particular regimens for administering this combination. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient.
    Type: Application
    Filed: October 27, 2010
    Publication date: November 3, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Carla HAEFNER, Gerhard STEINMANN, Jerry O. STERN, Chan-Loi YONG
  • Publication number: 20110268697
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Application
    Filed: July 6, 2011
    Publication date: November 3, 2011
    Inventors: Soojin Kim, Qi Gao, Fukang Yang
  • Patent number: 8048862
    Abstract: The embodiments provide compounds of the general Formulae I, II, III, IV, V, VI, VII, and X, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: November 1, 2011
    Assignee: InterMune, Inc.
    Inventors: Scott D. Seiwert, Leonid Beigelman, Brad Buckman, Antitsa Dimitrova Stoycheva, Steven B. Porter, Williamson Ziegler Bradford, Vladimir Serebryany
  • Publication number: 20110262525
    Abstract: This invention relates to compositions and methods useful for treating various cancers. Therapeutic combinations and methods of use thereof are also covered in the present application.
    Type: Application
    Filed: December 11, 2007
    Publication date: October 27, 2011
    Applicant: SCHERING CORPORATION
    Inventors: Yan Wang, Chen Zong, Cynthia Seidel-Dugan, Yaolin Wang, Siu-Long Yao, Brian Der-Hua Lu, Mohamad H. Ladha
  • Publication number: 20110256098
    Abstract: Disclosed are uses of immunotherapeutic compositions in combination with Standard of Care (SOC), or interferon therapy combined with anti-viral therapy, for the improved treatment of chronic hepatitis C virus (HCV) infection and related conditions, including liver function. The compositions, kits and uses of the invention, as compared to the use of SOC therapy alone: improves the rate of early response to therapy as measured by early virologic markers (e.g., RVR and EVR), enlarges the pool of patients who will have sustained responses to therapy over the long term, offers shortened courses of therapy for certain patients, enables “rescue” of patients who are non-responders or intolerant to SOC therapy, improves liver function and/or reduces liver damage in patients, and enables the personalization of HCV therapy for a patient, which can result in dose sparing, improved patient compliance, reduced side effects, and improved long term therapeutic outcomes.
    Type: Application
    Filed: September 18, 2009
    Publication date: October 20, 2011
    Inventors: David Apelian, Richard C. Duke, Alex Franzusoff
  • Publication number: 20110256099
    Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Application
    Filed: June 23, 2011
    Publication date: October 20, 2011
    Inventors: Kap-Sun Yeung, Kyle E. Parcella, John A. Bender, Brett R. Beno, Katharine A. Grant-Young, Ying Han, Piyasena Hewawasam, John F. Kadow, Andrew Nickel
  • Publication number: 20110250172
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: April 8, 2011
    Publication date: October 13, 2011
    Inventors: Yao-Ling Qiu, Ce Wang, Xiaowen Peng, Yat Sun Or
  • Publication number: 20110250177
    Abstract: The present invention provides biologically active variants of human ?-2b-interferon. The variants contain carboxy terminus truncations when compared with the amino acid sequence of full-length human ?-2b-interferon. It is the novel finding of the present invention that these truncated variants have the biological activity of full-length human ?-2b-interferon. The invention encompasses these biologically active variant ?-interferons, as well as polynucleotides encoding these interferons. Expression cassettes comprising these polynucleotides and host cells comprising the expression cassettes are also provided. The invention also provides compositions comprising variant ?-interferon polypeptides and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: May 11, 2011
    Publication date: October 13, 2011
    Applicant: Biolex Therapeutics, Inc.
    Inventors: Lynn Dickey, John Gasdaska, Kevin Cox
  • Publication number: 20110250176
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit Hepatitis C virus (HCV), compositions comprising such compounds, and methods for treating Hepatitis C using such combinations.
    Type: Application
    Filed: October 7, 2010
    Publication date: October 13, 2011
    Inventors: Julie A. Lemm, Stacey A. Voss, Min Gao, Susan E. Chaniewski, Amy K. Sheaffer, Fiona McPhee
  • Publication number: 20110250171
    Abstract: The invention relates to immunotherapeutic compounds and to methods for stimulating an immune response in a subject individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer or the compounds of the invention can be administered as a prophylactic to a subject individual to prevent or delay the development of cancer.
    Type: Application
    Filed: June 13, 2011
    Publication date: October 13, 2011
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Daniel P. Rossignol, Sally T. Ishizaka, Lynn D. Hawkins, Scott Z. Fields
  • Publication number: 20110250175
    Abstract: The present invention provides a TLR7 ligand and its use in therapeutic applications. Specifically, the present application provides a RNA oligonucleotide comprising a G:U wobble base pair in the context of a fully double-stranded structure and its use in treating disease such as viral infections, immune disorders and cancer.
    Type: Application
    Filed: March 17, 2010
    Publication date: October 13, 2011
    Inventors: Gunther Hartmann, Winfried Barchet, Vera Wimmenauer
  • Publication number: 20110250169
    Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby.
    Type: Application
    Filed: May 13, 2011
    Publication date: October 13, 2011
    Inventor: George N. Cox, III
  • Publication number: 20110250168
    Abstract: Methods of delivering a cargo moiety to a cell is provided according to embodiments of the invention which includes contacting a cell expressing sialoadhesin with a conjugate including a sialoadhesin binding moiety and a cargo moiety. The sialoadhesin binding moiety binds to the sialoadhesin expressed by the cell and is internalized along with the cargo, delivering the cargo moiety to the cell. Particular methods provided by the invention include induction or enhancement of sialoadhesin expression in a cell which naturally produces little or no sialoadhesin. Induction or enhancement of sialoadhesin expression includes transfection of a sialoadhesin expression construct and/or administration of an agent effective to induce or enhance sialoadhesin expression. Methods and compositions for stimulating an immune response in a subject are detailed. Particular methods and compositions for stimulating an immune response to a virus are provided by the invention.
    Type: Application
    Filed: April 11, 2011
    Publication date: October 13, 2011
    Inventors: Hans Nauwynck, Peter Delputte
  • Publication number: 20110243891
    Abstract: The present invention relates to a compound of General Formula (I) below, among others. In the Formula, Ar1 is an optionally substituted aryl or heteroaryl group; R1 is a hydrogen atom, an optionally substituted C1-C6 alkyl group, or an optionally substituted aryl, aralkyl, or heteroaryl group; R2 is an optionally substituted aryl, aralkyl, or heteroaryl group; and R3 is a hydrogen atom or a C1-C6 alkyl group. A compound of the present invention has an excellent Weel kinase inhibiting effect, and is therefore useful in the filed of medicine, particularly in various types of cancer therapy.
    Type: Application
    Filed: December 9, 2009
    Publication date: October 6, 2011
    Inventors: Makoto Bamba, Hidetomo Furuyama, Toshihiro Sakamoto, Satoshi Sunami, Keiji Takahashi, Fuyuki Yamamoto, Takashi Yoshizumi
  • Publication number: 20110243841
    Abstract: Disclosed herein are methods and compositions comprising anti-CD74 and/or anti-HLA-DR antibodies for treatment of GVHD and other immune dysfunction diseases. In preferred embodiments, the anti-CD74 and/or anti-HLA-DR antibodies are effective to deplete antigen-presenting cells, such as dendritic cells. Most preferably, administration of the therapeutic compositions depletes all subsets of APCs, including mDCs, pDCs, B cells and monocytes, without significant depletion of T cells. In alternative embodiments, administration of the therapeutic compositions suppresses proliferation of allo-reactive T cells, while preserving cytomegalovirus (CMV)-specific, CD8+ memory T cells. The compositions and methods provide a novel conditioning regimen for preventing aGVHD and/or treating chronic GVHD, without altering preexisting anti-viral immunity.
    Type: Application
    Filed: March 29, 2011
    Publication date: October 6, 2011
    Applicant: IMMUNOMEDICS, INC.
    Inventors: Chien-Hsing Chang, David M. Goldenberg
  • Publication number: 20110244027
    Abstract: The present invention relates to 2?-Fluoro-6?-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses.
    Type: Application
    Filed: May 13, 2011
    Publication date: October 6, 2011
    Applicant: University of Georgia Research Center
    Inventors: Chung K. Chu, Jianing Wang
  • Publication number: 20110243892
    Abstract: The present invention relates to Y-shape branched PEG derivatives of formulae (I) to (IV). The present invention also relates to conjugates of these Y-shape derivatives and drug molecules, pharmaceutical compositions comprising those conjugates.
    Type: Application
    Filed: June 17, 2011
    Publication date: October 6, 2011
    Inventors: Shishan Ji, Dequan Zhu
  • Publication number: 20110243894
    Abstract: The present invention provides methods of treating hepatitis C virus (HCV) infection; methods of reducing the incidence of complications associated with HCV and cirrhosis of the liver; and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from HCV infection. Also provided are methods of treating liver steatosis and liver fibrosis.
    Type: Application
    Filed: April 1, 2011
    Publication date: October 6, 2011
    Inventors: Melanie Ott, Eva Herker, Robert V. Farese, Charles Harris
  • Publication number: 20110236304
    Abstract: The present invention provides substituted humanized, chimeric or human anti-CD20 antibodies or antigen binding fragments thereof and bispecific antibodies or fusion proteins comprising the substituted antibodies or antigen binding fragments thereof. The antibodies, fusion proteins or fragments are useful for treatment of B-cell disorders, such as B-cell malignancies and autoimmune diseases, as well as GVHD, organ transplant rejection, and hemolytic anemia and cryoglobulinemia. Amino acid substitutions, particularly substitution of an aspartate residue at Kabat position 101 of CDR3 VH (CDRH3), result in improved therapeutic properties, such as decreased dissociation rates, improved CDC activity, improved apoptosis, improved B-cell depletion and improved therapeutic efficacy at very low dosages.
    Type: Application
    Filed: March 1, 2011
    Publication date: September 29, 2011
    Applicant: IMMUNOMEDICS, INC.
    Inventors: David M. GOLDENBERG, Chien-Hsing CHANG, Hans J. HANSEN
  • Publication number: 20110236352
    Abstract: The present invention concerns methods and compositions for forming PEGylated complexes of defined stoichiometry and structure. In preferred embodiments, the PEGylated complex is formed using dock-and-lock technology, by attaching a target agent to a DDD sequence and attaching a PEG moiety to an AD sequence and allowing the DDD sequence to bind to the AD sequence in a 2:1 stoichiometry, to form PEGylated complexes with two target agents and one PEG moiety. In alternative embodiments, the target agent may be attached to the AD sequence and the PEG to the DDD sequence to form PEGylated complexes with two PEG moieties and one target agent. In more preferred embodiments, the target agent may comprise any peptide or protein of physiologic or therapeutic activity. The PEGylated complexes exhibit a significantly slower rate of clearance when injected into a subject and are of use for treatment of a wide variety of diseases.
    Type: Application
    Filed: June 1, 2011
    Publication date: September 29, 2011
    Applicant: IBC PHARMACEUTICALS, INC.
    Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
  • Publication number: 20110236351
    Abstract: The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms.
    Type: Application
    Filed: March 24, 2011
    Publication date: September 29, 2011
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Robert S. Kauffman, Cyrill Jean Camille Titeux, Ramon Polo, Rudolf Peter Gerhardt Van Heeswijk, Maria Gloria Beumont, Gaston Rafael Picchio
  • Publication number: 20110236349
    Abstract: The present invention provides methods of treating a viral infection in an individual. The methods generally involve administering to an individual an effective amount of an epidermal growth factor receptor (EGF-R) inhibitor.
    Type: Application
    Filed: December 16, 2009
    Publication date: September 29, 2011
    Inventors: Jonathan L. Koff, Jay A. Nadel